J. Perfect
Clinical Infectious Diseases · 2000–2020
A researcher in the Science corpus: 16 papers; trusts 0 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Whom J. Perfect trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts J. Perfect overall
Papers from J. Perfect's perspective
Ordered by how strongly the researchers J. Perfect trusts endorse each paper. Same corpus, a different order for every researcher.
- Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. (Clinical Infectious Diseases)
- Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. (New England Journal of Medicine)
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. (New England Journal of Medicine)
- Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. (Clinical Infectious Diseases)
- Comparison of caspofungin and amphotericin B for invasive candidiasis. (New England Journal of Medicine)
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. (The Lancet)
- Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (Clinical Microbiology Reviews)
- Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. (Clinical Infectious Diseases)
- Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality (Antimicrobial Agents and Chemotherapy)
- Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. (New England Journal of Medicine)
Their papers
- Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance (2020) — 778 citations
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (2019) — 2,463 citations
- The antifungal pipeline: a reality check (2017) — 721 citations
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. (2016) — 607 citations
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America (2010) — 2,476 citations
- Human Dectin-1 Deficiency and Mucocutaneous Fungal Infections (2009) — 740 citations
- Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008) — 4,849 citations
- Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008) — 599 citations
- Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. (2007) — 749 citations
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. (2007) — 1,520 citations
- Voriconazole treatment for less-common, emerging, or refractory fungal infections. (2003) — 671 citations
- Sexual Cycle of Cryptococcus neoformans var. grubii and Virulence of Congenic a and α Isolates (2003) — 359 citations
- Comparison of caspofungin and amphotericin B for invasive candidiasis. (2002) — 1,238 citations
- Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. (2002) — 951 citations
- Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. (2001) — 632 citations
- Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. (2000) — 1,020 citations